Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Selpercatinib (LOXO-292) in Healthy Adults
NCT05338515Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2019
- Primary completion
- Mar 2019
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label trial of selpercatinib in non-small cell lung cancer (NSCLC), thyroid cancer and Medullary Thyroid Cancer (MTC) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) Considered Related to Study Drug. Started Feb 2019; status: completed.
02
Drugs
selpercatinib
03
Conditions
non-small cell lung cancer (NSCLC)thyroid cancerMedullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NCT05338515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05338515.